Experiences with Antithyroid

91 public posts

Info for People with Graves'/Hyperthyroidism

The full leaflet is available here: https://www.btf-thyroid.org/antithyroid-drug-therapy-to-treat-hyperthyroidismleafletThe full leaflet is available here: https://www.btf-thyroid.org/antithyroid-drug-therapy-to-treat-hyperthyroidismleaflet

Valarianin Thyroid UK

Long term antithyroid medication

In patients hoping to avoid ablative therapy, continuous antithyroid drug therapy for >5 years is reasonable.”In patients hoping to avoid ablative therapy, continuous antithyroid drug therapy for >5 years is reasonable.”

Coconuttyin Thyroid UK

Patients treated for hyperthyroidism are at increased risk of becoming obese: findings from a large prospective secondary care cohort

Next, we investigated the effect of treatment with antithyroid drug alone in regard to antithyroid drug with radioiodine therapy. We modelled the longitudinal weight data in relation to the treatment pathway to thyroid function and the need for long-term thyroxine replacement.Next, we investigated the effect of treatment with antithyroid drug alone in regard to antithyroid drug with radioiodine therapy. We modelled the longitudinal weight data in relation to the treatment pathway to thyroid function and the need for long-term thyroxine replacement.

helvellaAdministratorin Thyroid UK

Want to take advantage of all our features? Just log in!

High Free T4

November 4, 2019 TSH 2.07 uIU/mL T4 - 1.87 THYROXINE13.38 ug/dL(4.60 - 12.00ug/dL) T3 UPTAKE0.93(0.76 - 1.25) FREE THYROXINE INDEX(12.444.40 - 11.40) TRIIODOTHYYRONINE1.11 ng/mL(0.80 - 2.00 ng/mL) ANTITHYROID PEROXIDA15.5 IU/mL(<=8.9 IU/mL) 12:57pm 112 mcg Levoxyl everyday September 26, 2019 TSH 4.03November 4, 2019 TSH 2.07 uIU/mL T4 - 1.87 THYROXINE13.38 ug/dL(4.60 - 12.00ug/dL) T3 UPTAKE0.93(0.76 - 1.25) FREE THYROXINE INDEX(12.444.40 - 11.40) TRIIODOTHYYRONINE1.11 ng/mL(0.80 - 2.00 ng/mL) ANTITHYROID PEROXIDA15.5 IU/mL(<=8.9 IU/mL) 12:57pm 112 mcg Levoxyl everyday September 26, 2019 TSH 4.03

wsn104in Thyroid UK

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830376/ Whilst I don't agree especially with the cost effectiveness bits comparing ATD therapy to RAI or TT, this piece is chocked full of details about ATD, RAI, TT. Worth a read since many of us always wonder how long we can go on with Graves on ATD therapyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830376/ Whilst I don't agree especially with the cost effectiveness bits comparing ATD therapy to RAI or TT, this piece is chocked full of details about ATD, RAI, TT. Worth a read since many of us always wonder how long we can go on with Graves on ATD therapy

lingin Thyroid UK

Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema from The Lancet

earlier, he had been diagnosed with autoimmune hypothyroidism after he began to gain weight and complained of feeling tired: his thyroid-stimulating hormone (TSH) concentration was raised at 83 mIU/L (normal range 0·3–4·6), free thyroxine (T4) concentration was 5·9 pmol/L (normal range 10–23), and the antithyroidearlier, he had been diagnosed with autoimmune hypothyroidism after he began to gain weight and complained of feeling tired: his thyroid-stimulating hormone (TSH) concentration was raised at 83 mIU/L (normal range 0·3–4·6), free thyroxine (T4) concentration was 5·9 pmol/L (normal range 10–23), and the antithyroid

holyshedballsin Thyroid UK

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study An abstract

Compared with patients in the antithyroid drug group, mortality was lower among those in radioiodine group A (HR 0·50, 95% CI 0·29–0·85), but not for those in radioiodine group B (HR 1·51, 95% CI 0·96–2·37).Compared with patients in the antithyroid drug group, mortality was lower among those in radioiodine group A (HR 0·50, 95% CI 0·29–0·85), but not for those in radioiodine group B (HR 1·51, 95% CI 0·96–2·37).

holyshedballsin Thyroid UK

Graves' Disease: Can It Be Cured?

Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score.Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score.

helvellaAdministratorin Thyroid UK

GRAVES : DEVELOPMENT OF THE CLINICAL PICTURE AND THE COURSE OF THE DISEASE

During the course of therapy, the 20-minute technetium uptake test was repeatedly measured while the patient received both antithyroid drugs and suppressive doses of T3; suppressibility of the thyroid gradually fell to the normal range.During the course of therapy, the 20-minute technetium uptake test was repeatedly measured while the patient received both antithyroid drugs and suppressive doses of T3; suppressibility of the thyroid gradually fell to the normal range.

lingin Thyroid UK

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study

Abstract BACKGROUND: Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain.Abstract BACKGROUND: Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain.

helvellaAdministratorin Thyroid UK

Thyroid eye disease (TED) symptoms, diagnosis and treatment options.

Neither thyroidectomy (typically partial) nor antithyroid drugs influence the course of the orbitopathy. 17.Neither thyroidectomy (typically partial) nor antithyroid drugs influence the course of the orbitopathy. 17.

lingin Thyroid UK

Clinical Utility of TSH Receptor Antibodies (TRAb)

TRAb can accurately predict short-term relapses of hyperthyroidism after a course of antithyroid drugs but are less effective in predicting long-term relapses or remissions. 9. GD affects many organ systems either by the autoimmune process or as a complication of thyrotoxicosis.TRAb can accurately predict short-term relapses of hyperthyroidism after a course of antithyroid drugs but are less effective in predicting long-term relapses or remissions. 9. GD affects many organ systems either by the autoimmune process or as a complication of thyrotoxicosis.

lingin Thyroid UK

Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial

Patients: 150 patients aged 18 to 79 years with persistent Hashimoto-related symptoms despite euthyroid status while receiving hormone replacement therapy and with serum antithyroid peroxidase (anti-TPO) antibody titers greater than 1000 IU/mL.Patients: 150 patients aged 18 to 79 years with persistent Hashimoto-related symptoms despite euthyroid status while receiving hormone replacement therapy and with serum antithyroid peroxidase (anti-TPO) antibody titers greater than 1000 IU/mL.

holyshedballsin Thyroid UK

Am I ready for medication?

TSH Ultrasensitive Result 4.37 - Ref range 0.27 - 4.20 T4 Free Result 12 - Ref range 12 - 22 Free T3 Result 4.1 - Ref range 4.0 - 6.8 Antithyroid Microsomal Positive Titre 1:6400 - Less than 1:100 = Negative More than 1:10 = positive Antithyroidthyroglobin Negative- Less than 1:10 = negativeMore thanTSH Ultrasensitive Result 4.37 - Ref range 0.27 - 4.20 T4 Free Result 12 - Ref range 12 - 22 Free T3 Result 4.1 - Ref range 4.0 - 6.8 Antithyroid Microsomal Positive Titre 1:6400 - Less than 1:100 = Negative More than 1:10 = positive Antithyroidthyroglobin Negative- Less than 1:10 = negativeMore than

Goforitmumin Thyroid UK

Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial

PR4NOWin Thyroid UK

Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial

[/i] [i]Patients:[/i] [i]150 patients aged 18 to 79 years with persistent Hashimoto-related symptoms despite euthyroid status while receiving hormone replacement therapy and with serum antithyroid peroxidase (anti-TPO) antibody titers greater than 1000 IU/mL.[/i] [i]Patients:[/i] [i]150 patients aged 18 to 79 years with persistent Hashimoto-related symptoms despite euthyroid status while receiving hormone replacement therapy and with serum antithyroid peroxidase (anti-TPO) antibody titers greater than 1000 IU/mL.

helvellaAdministratorin Thyroid UK